 |
(S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one) |
|---|---|
| Trade Name | |
| Orphan Indication | T-cell lymphoma |
| USA Market Approval | USA |
| USA Designation Date | 2017-12-18 00:00:00 |
| Sponsor | Rhizen Pharmaceuticals SA;40 Rue Fritz-Courvoisier;La Chaux-de-Fonds |
